ACHEMA 2022 will take place at Messe Frankfurt, Germany on August 22-26, 2022. Pharmadule-Morimatsu will attend the conference to discuss new developments in the industry with industry experts on modular facilities, process systems, bioreactors and other products. At the conference, we will also present our latest projects. If you’d like to have more in-depth conversations with us on site, do not hesitate to contact us in advance to schedule a meeting. Pharmadule-Morimatsu is looking forward to having fruitful discussions and sharing experience with industry players which will jointly contribute to the development of the industry.

【Booth Information】

-   Date: 22^nd-26^th August

-   Place: Frankfurt am Main, Germany

-   Location: Hall 9.1 Booth D42

【About Pharmadule-Morimatsu】

Since 1986, Pharmadule has successfully delivered more than 80 manufacturing facilities in the pharmaceutical and biopharmaceutical industries and completed more than 300 engineering design and validation programs. We have international project delivery experience and are familiar with regulatory requirements in different regions, providing engineering and solutions to pharmaceutical and biopharmaceutical clients worldwide.

modular factory

Process Solution

2011, Pharmadule was acquired by Morimatsu Group and established Pharmadule-Morimatsu, with headquarters in Stockholm, Sweden. Morimatsu originated from Japan and is a well-known supplier of core process equipment and process modules in the industry. The modular facility realizes the combination of facility building and process, so that the needs of process, operation, maintenance, safety, energy saving, and other aspects can be considered in a unified manner, which is more conducive to optimizing the overall layout of the facility building and process flow, and providing clients with high-quality, integrated solutions.

About Morimatsu Life Science

Morimatsu Life Science is the sanitary business segment of Morimatsu International Holding Co., Ltd. (Morimatsu International, stock code: 2155.HK), covering industries such as pharmaceuticals, biopharmaceuticals, FMCG, cosmetic and electronic chemicals, and mainly includes Shanghai Morimatsu Pharmaceutical Equipment Engineering Co., Ltd., Morimatsu (Suzhou) Life Technology Co., Ltd., Shanghai Morimatsu Biotechnology Co., Ltd., Pharmadule Morimatsu AB (Sweden) and other companies and their affiliates, focusing on the research and development, manufacturing and sales of products in related fields. Morimatsu, founded in Japan and taken root in China, has developed into a multi-national company that embraces globalization, masters core technology, and gains rich experience from project implementation in diverse fields including core equipment, process systems, and engineering solutions. Starting from its advanced manufacturing base in China, Morimatsu International has opened subsidiaries in Sweden, the United States, India and Italy, and has delivered different forms of products and services to more than 40 countries and regions so far, by virtue of its global footprint of efficient and professional team.

Forward-Looking Statements

The information in this press release may include some forward-looking statements. Such statements are essentially susceptible to considerable risks and uncertainties. The use of “predicted”, “believed”, “forecast”, “planned” and/or other similar words/phrases in all statements related to our company is to indicate that the statements are forward-looking ones. Our company undertakes no obligation to constantly revise such predicted statements.

Forward-looking statements are based on our company management’s current perspectives, assumptions, expectations, estimations, predictions and understanding of future affairs at the time of the making of such statements. Such statements are not guaranties of future development and are susceptible to the impact of risks, uncertainties and other factors; some are beyond the control of our company and unpredictable. Subject to the influence of future changes and development in our business, competition environment, political, economic, legal and social conditions, the actual outcomes may differ significantly from the information contained in the forward-looking statements.